References
Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, & Dinarello CA (2020). Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res 126: 1260-1280.
Alessi MC, Cenac N, Si-Tahar M, & Riteau B (2017). FPR2: A Novel Promising Target for the Treatment of Influenza. Front Microbiol 8: 1719.
Almond MH, Edwards MR, Barclay WS, & Johnston SL (2013). Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax 68: 684-686.
Bauer RN, Brighton LE, Mueller L, Xiang Z, Rager JE, Fry RC, et al. (2012). Influenza enhances caspase-1 in bronchial epithelial cells from asthmatic volunteers and is associated with pathogenesis. J Allergy Clin Immunol 130: 958-967 e914.
Bosnar M, Cuzic S, Bosnjak B, Nujic K, Ergovic G, Marjanovic N, et al. (2011). Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia. Int Immunopharmacol 11: 424-434.
Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, & Perretti M (2011). Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J Immunol 186: 4905-4914.
Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, Flower RJ, et al. (2013). A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 122: 608-617.
Cahill CM, & Rogers JT (2008). Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem 283: 25900-25912.
Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. (2020). Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 382: 1787-1799.
Chen W, Zhao M, Zhao S, Lu Q, Ni L, Zou C, et al. (2017). Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline. Inflamm Res 66: 157-166.
Chen X, Wang N, Zhu Y, Lu Y, Liu X, & Zheng J (2017). The Antimalarial Chloroquine Suppresses LPS-Induced NLRP3 Inflammasome Activation and Confers Protection against Murine Endotoxic Shock. Mediators Inflamm 2017: 6543237.
Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, et al. (2020). Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. Mol Metab 39: 101009.
Cure E, Kucuk A, & Cumhur Cure M (2020). Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol Int 40: 1177-1179.
Dinarello CA (2009). Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519-550.
Dixon AE, & Peters U (2018). The effect of obesity on lung function. Expert Rev Respir Med 12: 755-767.
Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et al. (2010). Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 184: 2611-2619.
Fink SL, & Cookson BT (2005). Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 73: 1907-1916.
Furuya MY, Asano T, Sumichika Y, Sato S, Kobayashi H, Watanabe H, et al. (2018). Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. Arthritis Res Ther 20: 196.
Galvao I, de Carvalho RVH, Vago JP, Silva ALN, Carvalho TG, Antunes MM, et al. (2020). The role of annexin A1 in the modulation of the NLRP3 inflammasome. Immunology 160: 78-89.
Grant RW, & Dixit VD (2013). Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol 4: 50.
Green WD, & Beck MA (2017). Obesity Impairs the Adaptive Immune Response to Influenza Virus. Ann Am Thorac Soc 14: S406-S409.
Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, & Zlabinger GJ (2015). Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. Sci Rep 5: 12016.
Guan M, Ma H, Fan X, Chen X, Miao M, & Wu H (2020). Dexamethasone alleviate allergic airway inflammation in mice by inhibiting the activation of NLRP3 inflammasome. Int Immunopharmacol 78:106017.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382: 1708-1720.
Hong Z, Jiang Z, Liangxi W, Guofu D, Ping L, Yongling L, et al.(2004). Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol 4: 223-234.
Hotamisligil GS (2017). Inflammation, metaflammation and immunometabolic disorders. Nature 542: 177-185.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506.
Huttunen R, & Syrjanen J (2010). Obesity and the outcome of infection. Lancet Infect Dis 10: 442-443.
Huttunen R, & Syrjanen J (2013). Obesity and the risk and outcome of infection. Int J Obes (Lond) 37: 333-340.
Ikonomidis I, Pavlidis G, Katsimbri P, Andreadou I, Triantafyllidi H, Tsoumani M, et al. (2019). Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clin Res Cardiol 108: 1093-1101.
Iyer SS, He Q, Janczy JR, Elliott EI, Zhong Z, Olivier AK, et al.(2013). Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 39: 311-323.
Jia X, Liu B, Bao L, Lv Q, Li F, Li H, et al. (2018). Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. PLoS Pathog 14:e1007428.
Jia X, Yin C, Lu S, Chen Y, Liu Q, Bai J, et al. (2020). Two Things about COVID-19 Might Need Attention. Preprints.
Jorgensen I, Zhang Y, Krantz BA, & Miao EA (2016). Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis. J Exp Med 213: 2113-2128.
Karlsson EA, Sheridan PA, & Beck MA (2010). Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol 184: 3127-3133.
Kelley N, Jeltema D, Duan Y, & He Y (2019). The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci 20.
Ko JH, Yoon SO, Lee HJ, & Oh JY (2017). Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NFkappaB pathways in autophagy- and p62-dependent manners. Oncotarget 8:40817-40831.
Kopitar-Jerala N (2017). The Role of Interferons in Inflammation and Inflammasome Activation. Front Immunol 8: 873.
Kwong JC, Campitelli MA, & Rosella LC (2011). Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 53: 413-421.
Latz E, & Duewell P (2018). NLRP3 inflammasome activation in inflammaging. Semin Immunol 40: 61-73.
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. (2020). Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission.
. Clin Infect Dis
Lippi G, Mattiuzzi C, Bovo C, & Plebani M (2020). Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomed 91: 137-145.
Lopategi A, Flores-Costa R, Rius B, Lopez-Vicario C, Alcaraz-Quiles J, Titos E, et al. (2019). Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. J Leukoc Biol 105: 25-36.
Lopez-Castejon G, & Pelegrin P (2012). Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs 21: 995-1007.
Lu Y, Xiao G, & Luo W (2016). Minocycline Suppresses NLRP3 Inflammasome Activation in Experimental Ischemic Stroke. Neuroimmunomodulation 23: 230-238.
Lupfer C, Malik A, & Kanneganti TD (2015). Inflammasome control of viral infection. Curr Opin Virol 12: 38-46.
Machado MG, Tavares LP, Souza GVS, Queiroz-Junior CM, Ascencao FR, Lopes ME, et al. (2020). The Annexin A1/FPR2 pathway controls the inflammatory response and bacterial dissemination in experimental pneumococcal pneumonia. FASEB J 34: 2749-2764.
Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, & Guimaraes MZ (2011). Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol 163: 912-926.
Mastrocola R, Aragno M, Alloatti G, Collino M, Penna C, & Pagliaro P (2018). Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome. Curr Med Chem 25:1294-1310.
Mastrocola R, Collino M, Penna C, Nigro D, Chiazza F, Fracasso V, et al. (2016). Maladaptive Modulations of NLRP3 Inflammasome and Cardioprotective Pathways Are Involved in Diet-Induced Exacerbation of Myocardial Ischemia/Reperfusion Injury in Mice. Oxid Med Cell Longev 2016: 3480637.
Milner JJ, & Beck MA (2012). The impact of obesity on the immune response to infection. Proc Nutr Soc 71: 298-306.
Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, et al. (2013). Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 14: 52-60.
Netea MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, van Crevel R, van de Veerdonk FL, et al. (2020). Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell 181: 969-977.
Nidorf SM, Eikelboom JW, & Thompson PL (2014). Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. J Cardiovasc Pharmacol Ther 19: 45-52.
Norling LV, Dalli J, Flower RJ, Serhan CN, & Perretti M (2012). Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol 32: 1970-1978.
O’Riordan CE, Purvis GSD, Collotta D, Chiazza F, Wissuwa B, Al Zoubi S, et al. (2019). Bruton’s Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice. Front Immunol 10: 2129.
Otani K, Watanabe T, Shimada S, Takeda S, Itani S, Higashimori A, et al. (2016). Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci Rep 6: 32587.
Perretti M, & D’Acquisto F (2009). Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9:62-70.
Pinar AA, Scott TE, Huuskes BM, Tapia Caceres FE, Kemp-Harper BK, & Samuel CS (2020). Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacol Ther 209: 107511.
Potenza MA, Nacci C, De Salvia MA, Sgarra L, Collino M, & Montagnani M (2017). Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacol Res 120: 226-241.
Powell N, Lo JW, Biancheri P, Vossenkamper A, Pantazi E, Walker AW, et al. (2015). Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation. Gastroenterology 149: 456-467 e415.
Ratajczak MZ, & Kucia M (2020). SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine ”storm” and risk factor for damage of hematopoietic stem cells. Leukemia.
Rayamajhi M, Zhang Y, & Miao EA (2013). Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods Mol Biol 1040: 85-90.
Ruan Q, Yang K, Wang W, Jiang L, & Song J (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46(5): 846-848.
Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. (2020). COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 38: 337-342.
Serhan CN, Chiang N, & Dalli J (2015). The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol 27: 200-215.
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. (2020). Lille Intensive Care COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. . Obesity (Silver Spring).
Singh AK, Gupta R, Ghosh A, & Misra A (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 14: 303-310.
Sodhi M, & Etminan M (2020). Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. Pharmacotherapy 40: 487-488.
Sun NN, Yu CH, Pan MX, Zhang Y, Zheng BJ, Yang QJ, et al. (2017). Mir-21 Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts. Sci Rep 7: 14369.
Tack CJ, Stienstra R, Joosten LA, & Netea MG (2012). Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev 249: 239-252.
Tang TT, Lv LL, Pan MM, Wen Y, Wang B, Li ZL, et al. (2018). Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death Dis 9: 351.
Tschop MH, & DiMarchi RD (2012). Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies. Diabetes 61: 1309-1314.
Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. (2011). The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17: 179-188.
Wang Y, Liu X, Shi H, Yu Y, Yu Y, Li M, et al. (2020). NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. Clin Transl Med 10:91-106.
Wanjalla CN, McDonnell WJ, Barnett L, Simmons JD, Furch BD, Lima MC, et al. (2019). Adipose Tissue in Persons With HIV Is Enriched for CD4(+) T Effector Memory and T Effector Memory RA(+) Cells, Which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With Increasing Glucose Intolerance. Front Immunol 10: 408.
Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, et al. (2008). Feeding our immune system: impact on metabolism. Clin Dev Immunol 2008: 639803.
Wu R, Liu X, Yin J, Wu H, Cai X, Wang N, et al. (2018). IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice. Metabolism 83: 18-24.
Xu Y, Ma LL, Zhou C, Zhang FJ, Kong FJ, Wang WN, et al. (2013). Hypercholesterolemic myocardium is vulnerable to ischemia-reperfusion injury and refractory to sevoflurane-induced protection. PLoS One 8: e76652.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8: 420-422.
Yan R, Zhang Y, Li Y, Xia L, Guo Y, & Zhou Q (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367: 1444-1448.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8: 475-481.
Yang Y, Wang H, Kouadir M, Song H, & Shi F (2019). Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 10: 128.
Yap JKY, Moriyama M, & Iwasaki A (2020). Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. J Immunol.
Zhang X, Zhang G, Ren Y, Lan T, Li D, Tian J, et al. (2018). Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo. Eur J Pharmacol 834: 288-294.
Zhao C, & Zhao W (2020). NLRP3 Inflammasome-A Key Player in Antiviral Responses. Front Immunol 11: 211.
Zhao M, Bai M, Ding G, Zhang Y, Huang S, Jia Z, et al. (2018). Angiotensin II Stimulates the NLRP3 Inflammasome to Induce Podocyte Injury and Mitochondrial Dysfunction. Kidney Dis (Basel) 4:83-94.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062.
Zuurbier C, Abbate A, Cabrera-Fuentes H, Cohen M, Collino M, De Kleijn D, et al. (2019). Innate immunity as a target for acute cardioprotection. . Cardiovasc Res 115: 1131-1142.